摘要
目的探讨糖蛋白抑制剂联合化疗对子宫内膜癌患者血清中PD-L1和CD8表达及患者生存质量的影响。方法选取子宫内膜癌患者68例作为观察对象,随机分成2组,各34例。检测2组血清中PD-L1和CD8+表达水平,对疗效和患者生存质量进行评价。结果治疗后,观察组的客观缓解率高于对照组(P<0.05),2组疾病控制率比较无显著差异(P>0.05)。治疗前,2组PD-L1、CD8+水平无显著变化(P>0.05);治疗后,观察组PD-L1、CD8+水平比治疗前降低(P<0.05),且比对照组低(P<0.05);对照组PD-L1、CD8+水平与治疗前比较差异无统计学意义(P>0.05)。治疗后,2组KPS、QLQ-C30评分均较治疗前显著升高(P<0.05),且治疗后观察组KPS、QLQ-C30评分明显高于对照组(P<0.05)。治疗后,观察组患者不良反应发生率明显低于对照组(P<0.05)。结论糖蛋白抑制剂辅助治疗子宫内膜癌的效果明显,能明显提高患者的免疫系统功能,改善生活质量,减少不良反应,值得在临床上推广应用。
Objective To explore the effect of glycoprotein inhibitor combined with chemotherapy on the expression of PD-L1 and CD8 in the serum of patients with endometrial cancer and the quality of life of the patients.Methods 68 patients with endometrial cancer were selected and divided into 2 groups.The serum PD-L1 and CD8+expression levels in the 2 groups were detected to evaluate the efficacy and quality of life of the patients.Results After treatment,the objective remission rate of the observation group was higher than that of the control group(P<0.05),and there was no significant difference in the disease control rate between the 2 groups(P>0.05).Before treatment,the levels of PD-L1 and CD8+in the 2 groups had no significant changes(P>0.05);after treatment,the levels of PD-L1 and CD8+in the observation group were lower than before treatment(P<0.05),and lower than those in the control group(P<0.05);The levels of PD-L1 and CD8+in the control group were not significantly different from those before treatment(P>0.05).After treatment,the scores of KPS and QLQ-C30 in the 2 groups were significantly higher than those before treatment(P<0.05),and the scores of KPS and QLQ-C30 in the observation group after treatment were significantly higher than those in the control group(P<0.05).After treatment,the incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Glycoprotein inhibitors have obvious anti-tumor effects in adjuvant treatment of endometrial cancer patients,which can significantly improve the patient's immune system function,improve the quality of life,and reduce adverse reactions.It is worthy of clinical application.
作者
余花艳
史中州
仓顺东
YU Huayan;SHI Zhongzhou;CANG Shundong(The Second People's Hospital of Pingdingshan,Pingdingshan,467000)
出处
《实用癌症杂志》
2022年第5期786-789,共4页
The Practical Journal of Cancer